Redeye provides an initial take following the release of Optomed’s Q4 2024 report. Sales aligned with our expectations, and costs were a bit higher than projected. Overall, we note that the company has a positive outlook for 2025, which will be an important year for the company. We will provide an update, digging deeper into the report.
LÄS MER